Intra-Cellular Therapies Inc. (ITCI) Stake Raised by Franklin Street Advisors Inc. NC

Franklin Street Advisors Inc. NC increased its holdings in Intra-Cellular Therapies Inc. (NASDAQ:ITCI) by 236.6% in the fourth quarter, HoldingsChannel.com reports. The firm owned 54,060 shares of the biopharmaceutical company’s stock after purchasing an additional 38,000 shares during the period. Franklin Street Advisors Inc. NC’s holdings in Intra-Cellular Therapies were worth $783,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in ITCI. Perceptive Advisors LLC purchased a new stake in shares of Intra-Cellular Therapies in the third quarter valued at $14,667,000. Wasatch Advisors Inc. grew its position in shares of Intra-Cellular Therapies by 65.1% in the second quarter. Wasatch Advisors Inc. now owns 1,659,513 shares of the biopharmaceutical company’s stock valued at $20,611,000 after purchasing an additional 654,400 shares during the period. Alyeska Investment Group L.P. purchased a new stake in shares of Intra-Cellular Therapies in the third quarter valued at $8,663,000. Dimensional Fund Advisors LP grew its position in shares of Intra-Cellular Therapies by 419.3% in the second quarter. Dimensional Fund Advisors LP now owns 647,187 shares of the biopharmaceutical company’s stock valued at $8,038,000 after purchasing an additional 522,565 shares during the period. Finally, Goldman Sachs Group Inc. grew its position in Intra-Cellular Therapies by 336.1% during the second quarter. Goldman Sachs Group Inc. now owns 580,770 shares of the biopharmaceutical company’s stock valued at $7,213,000 after acquiring an additional 447,586 shares during the period. 74.47% of the stock is owned by institutional investors and hedge funds.

In other news, CFO Lawrence J. Hineline sold 3,192 shares of the company’s stock in a transaction dated Thursday, January 4th. The stock was sold at an average price of $15.67, for a total value of $50,018.64. Following the completion of the sale, the chief financial officer now owns 68,686 shares of the company’s stock, valued at $1,076,309.62. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Sharon Mates sold 18,750 shares of the company’s stock in a transaction dated Monday, October 30th. The stock was sold at an average price of $15.75, for a total value of $295,312.50. Following the completion of the sale, the chief executive officer now directly owns 1,107,457 shares of the company’s stock, valued at approximately $17,442,447.75. The disclosure for this sale can be found here. Insiders sold 42,034 shares of company stock valued at $673,564 in the last ninety days. Company insiders own 21.00% of the company’s stock.

Shares of Intra-Cellular Therapies Inc. (ITCI) traded up $0.23 during midday trading on Wednesday, hitting $18.35. The stock had a trading volume of 271,511 shares, compared to its average volume of 790,467. Intra-Cellular Therapies Inc. has a 52 week low of $7.85 and a 52 week high of $22.67. The stock has a market capitalization of $988.95, a P/E ratio of -8.38 and a beta of 0.72.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.53). Intra-Cellular Therapies had a negative return on equity of 27.40% and a negative net margin of 28,038.35%. The company had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.06 million. During the same quarter in the prior year, the business earned ($0.70) earnings per share. The company’s revenue was up 675.0% compared to the same quarter last year. equities research analysts anticipate that Intra-Cellular Therapies Inc. will post -2.13 earnings per share for the current year.

A number of equities research analysts have issued reports on ITCI shares. ValuEngine downgraded Intra-Cellular Therapies from a “sell” rating to a “strong sell” rating in a research report on Sunday, December 31st. BidaskClub downgraded Intra-Cellular Therapies from a “sell” rating to a “strong sell” rating in a research report on Tuesday, December 12th. Zacks Investment Research raised Intra-Cellular Therapies from a “hold” rating to a “buy” rating and set a $16.00 price target for the company in a research report on Wednesday, January 3rd. SunTrust Banks raised Intra-Cellular Therapies from a “hold” rating to a “buy” rating in a research report on Wednesday, November 8th. Finally, Canaccord Genuity started coverage on Intra-Cellular Therapies in a research report on Friday, December 15th. They set a “buy” rating and a $31.00 price target for the company. Two analysts have rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $25.56.

ILLEGAL ACTIVITY NOTICE: “Intra-Cellular Therapies Inc. (ITCI) Stake Raised by Franklin Street Advisors Inc. NC” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The legal version of this report can be accessed at https://www.com-unik.info/2018/01/10/intra-cellular-therapies-inc-itci-stake-raised-by-franklin-street-advisors-inc-nc.html.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).

Want to see what other hedge funds are holding ITCI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intra-Cellular Therapies Inc. (NASDAQ:ITCI).

Institutional Ownership by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit